Skip to main content

Table 1 Effect of adjunctive devices on final health outcomes

From: Systematic review: comparative effectiveness of adjunctive devices in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention of native vessels

Outcome

N trials/N pooled

WMF (M)

RR

(95% CI)

I2

SOE*

N trials/N pooled

WMF (M)

RR

(95% CI)

I2

 

All eligible trials

Limited to good quality trials

Catheter Aspiration

         

   Mortality

11/10

7.92

0.69 (0.47 to 1.02)

0%

Low

10/10

8.08

0.70 (0.47 to 1.03)

0%

Myocardial

infarction

10/10

8.80

0.61 (0.36 to 1.04)

0%

Low

10/10

8.80

0.61 (0.36 to 1.04)

0%

   Stroke

5/4

0.79

3.18 (0.73 to 13.88)

0%

Insufficient

5/4

0.79

3.18 (0.73 to 13.88)

0%

Target

revascularization

9/9

9.48

0.79 (0.61 to 1.02)

0%

Low

9/9

9.48

0.79 (0.61 to 1.02)

0%

   MACE

11/11

12.43

0.73 (0.61 to 0.88)

0%

High

11/11

12.43

0.73 (0.61 to 0.88)

0%

   HRQoL

0

---

---

---

Insufficient

0

---

---

---

Mechanical Thrombectomy

         

   Mortality

5/4

7.80

1.19 (0.51 to 2.76)

54.9

Insufficient

5/4

7.80

1.19 (0.51 to 2.76)

54.9

Myocardial

infarction

5/3

8.98

0.71 (0.27 to 1.85)

0%

Insufficient

5/3

8.98

0.71 (0.27 to 1.85)

0%

   Stroke

5/4

5.79

2.42 (0.75 to 7.78)

0%

Insufficient

5/4

5.79

2.42 (0.75 to 7.78)

0%

Target

revascularization

5/3

6.22

0.87 (0.36 to 2.10)

39.2%

Insufficient

5/3

6.22

0.87 (0.36 to 2.10)

39.2%

   MACE

4/3

6.22

1.23 (0.50 to 3.01)

79.9%

Insufficient

4/3

6.22

1.23 (0.50 to 3.01)

79.9%

   HRQoL

0

---

---

---

Insufficient

0

---

---

---

Distal Filter Embolic Protection

         

   Mortality

5/5

10.84

0.97 (0.54 to 1.75)

0%

Insufficient

4/4

11.49

0.97 (0.53 to 1.79)

0%

Myocardial

infarction

5/4

11.22

0.72 (0.15 to 3.34)

39.8%

Insufficient

4/3

11.93

0.56 (0.06 to 5.02)

60%

   Stroke

1/0

1

1.51 (0.30 to 7.52)†

NA

Insufficient

1/0

1

1.51 (0.30 to 7.52)†

NA

Target

revascularization

3/2

13.36

1.61 (1.03 to 2.54)

NA

Low

3/2

13.36

1.61 (1.03 to 2.54)

NA

   MACE

5/5

10.84

1.34 (0.97 to 1.86)

0%

Moderate

4/4

11.49

1.36 (0.98 to 1.89)

0%

   HRQoL

0

---

---

---

Insufficient

0

---

---

---

Distal Balloon Embolic Protection

       

   Mortality

4/4

6

0.82 (0.45 to 1.51)

2.5%

Insufficient

4/4

6

0.82 (0.45 to 1.51)

2.5%

Myocardial

infarction

5/5

6

0.67 (0.29 to 1.57)

0%

Insufficient

5/5

6

0.67 (0.29 to 1.57)

0%

   Stroke

1

6

0.48 (0.10 to 2.22)†

NA

Insufficient

1/0

6

0.48 (0.10 to 2.22)†

NA

Target

revascularization

5/5

6

0.93 (0.61 to 1.42)

0%

Insufficient

5/5

6

0.93 (0.61 to 1.42)

0%

   MACE

6/5

6

0.87 (0.64 to 1.19)

0%

Insufficient

6/5

6

0.87 (0.64 to 1.19)

0%

   HRQoL

0

---

---

---

Insufficient

0

---

---

---

Proximal Balloon Embolic Protection

       

   Mortality

1/0

6

0.51 (0.11 to 2.33)†

NA

Insufficient

1/0

6

0.51 (0.11 to 2.33)†

NA

Myocardial

infarction

1/0

6

1.01 (0.24 to 4.33)†

NA

Insufficient

1/0

6

1.01 (0.24 to 4.33)†

NA

   Stroke

1/0

6

0.20 (0 to 1.93)†

NA

Insufficient

1/0

6

0.20 (0 to 1.93)†

NA

Target

revascularization

1/0

6

0.71 (0.29 to 1.75)†

NA

Insufficient

1/0

6

0.71 (0.29 to 1.75)†

NA

   MACE

1/0

6

0.74 (0.36 to 1.54)†

NA

Insufficient

1/0

6

0.74 (0.36 to 1.54)†

NA

   HRQoL

0

---

---

---

Insufficient

0

---

---

---

Embolic Protection Devices

         

   Mortality

10/10

8.11

0.87 (0.58 to 1.30)

0%

Insufficient

9/9

8.31

0.87 (0.57 to 1.31)

0%

Myocardial

infarction

11/10

8.08

0.83 (0.45 to 1.53)

0%

Insufficient

10/9

8.27

0.83 (0.45 to 1.55)

0%

   Stroke

3/3

3.74

0.68 (0.22 to 2.11)

0%

Insufficient

3/3

3.74

0.68 (0.22 to 2.11)

0%

Target

revascularization

9/8

8.60

1.11 (0.80 to 1.52)

10%

Insufficient

9/8

8.60

1.11 (0.80 to 1.52)

10%

   MACE

12/11

7.97

1.04 (0.84 to 1.29)

0%

Moderate

11/10

8.15

1.03 (0.82 to 1.29)

4%

   HRQoL

0

---

---

---

Insufficient

0

---

---

---

  1. Abbreviations: CI = confidence interval; HRQoL = health-related quality of life; m = months; MACE = major adverse cardiovascular events; N = number; NA = not applicable; RR = relative risk; SOE = strength of evidence; WMF = weighted mean follow-up
  2. * Strength of evidence is rated for the primary base analyses only. Subgroup analyses were not rated with strength of evidence; include limiting the analysis to trials of good methodological quality.
  3. †Result is based on a single trial